Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Quarterly results
Director departure
INFINITY PHARMACEUTICALS, INC. (INFI) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/14/2022 8-K Quarterly results
Docs: "Infinity Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update – MARIO-3 Update in Patients with 1L TNBC showing 52% increase in one-year progression free survival rate in ITT patient population compared to Impassion130 benchmark –"
08/09/2022 8-K Quarterly results
Docs: "Infinity Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update – Positive eganelisib data from two-year landmark analysis demonstrate durable survival benefit in urothelial cancer patients from MARIO-275 –"
05/03/2022 8-K Quarterly results
03/29/2022 8-K Quarterly results, Appointed a new director
Docs: "AMENDMENT NO. 1 TO 2019 EQUITY INCENTIVE PLAN OF INFINITY PHARMACEUTICALS, INC.",
"Infinity Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Company Highlights – MARIO-4, the first eganelisib registration-enabling trial, in front-line metastatic triple negative breast cancer expected to initiate by the end of 2022 –"
11/02/2021 8-K Quarterly results
Docs: "Infinity Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Company Update – Encouraging data for eganelisib in both PD-L1 and PD-L1 mTNBC patients, with meaningful prolongation of PFS over IMpassion130 reference benchmark –"
07/27/2021 8-K Quarterly results
Docs: "Infinity Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Company Update",
"9 2L UC MARIO-2751 1L TNBC MARIO-32",
"Infinity Pharmaceuticals Presents Updated Data from Phase 2 MARIO-275 Trial in Urothelial Cancer and Phase 2 MARIO-3 Trial in Triple Negative Breast Cancer"
03/16/2021 8-K Quarterly results
11/09/2020 8-K Quarterly results
Docs: "Infinity Pharmaceuticals Provides Company Update and Third Quarter 2020 Financial Results – MARIO-275 IDMC Determined that Risk/Benefit for Patients Warrants Resumption of Enrollment&#59; Infinity to Determine Next Steps by Year End –",
"Infinity Pharmaceuticals Presents New MARIO-1 Phase 1/1b Clinical Data at The Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting"
07/30/2020 8-K Quarterly results
05/11/2020 8-K Quarterly results
03/03/2020 8-K Quarterly results
10/30/2019 8-K Quarterly results
07/30/2019 8-K Quarterly results
Docs: "FORM 8-K",
"Amended and Restated Capital on Demand™ Sales Agreement, by and among Infinity Pharmaceuticals, Inc. and JonesTrading Institutional Services LLC and B. Riley FBR, Inc",
"Opinion of Wilmer Cutler Pickering Hale and Dorr LLP",
"Infinity Pharmaceuticals Provides Company Update and Second Quarter 2019 Financial Results — Initiated MARIO-275 Global, Randomized Phase 2 Study in I/O Naïve Urothelial Cancer — — Initiating MARIO-3 Phase 2 Study in Front-Line Triple Negative Breast and Renal Cell Cancer in 3Q"
05/07/2019 8-K Quarterly results
Docs: "Securities registered pursuant to Section 12 of the Act: Title of Class Trading Symbol Name of Exchange on Which Registered Common Stock, $0.001 par value INFI Nasdaq Global Select Market Item 2.02. Results of Operations and Financial Condition. On May 7, 2019, we issued a press release announcing our results for the quarter ended March 31, 2019 and will conduct a previously announced, publicly available conference call to discuss those results. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained on the websites referenced in the press release is not incorporated herein. This information and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities E...",
"Infinity Pharmaceuticals Provides Company Update and First Quarter 2019 Financial Results — MARIO-275 Phase 2 Study in I/O Naïve Urothelial Cancer Patients on Track to Initiate in 2Q19 — — MARIO-3 Phase 2 Study in Front-Line Triple Negative Breast Cancer and Renal Cell Cancer Patients on Track to Initiate in 3Q19 — — Infinity Received Net Proceeds of $22.9M in Non-Dilutive Capital from the Monetization of Copiktra ™ Royalties and a Phase 3 Milestone from PellePharm"
03/14/2019 8-K Quarterly results
Docs: "SIGNATURE",
"Infinity Pharmaceuticals Reports Full Year 2018 Financial Results and Provides Company Update"
11/05/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report : November 5, 2018 Infinity Pharmaceuticals, Inc. Delaware 000-31141 33-0655706 784 Memorial Drive, Cambridge, MA 02139 Registrant's telephone number, including area code: 453-1000 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement c...",
"Infinity Pharmaceuticals Provides Company Update and Third Quarter 2018 Financial Results",
"Bristol-Myers Squibb and Infinity Pharmaceuticals Announce a New Clinical Collaboration to Evaluate Opdivo in Combination with IPI-549 in Urothelial Cancer"
08/07/2018 8-K Quarterly results
Docs: "Infinity Pharmaceuticals Provides Company Update and Second Quarter 2018 Financial Results"
05/08/2018 8-K Quarterly results
Docs: "FORM 8-K",
"Infinity Pharmaceuticals Provides Company Update and First Quarter 2018 Financial Results"
03/15/2018 8-K Quarterly results
Docs: "FORM 8-K",
"Infinity Pharmaceuticals Provides Company Update and Reports Fourth Quarter and Full Year 2017 Financial Results"
11/07/2017 8-K Quarterly results
Docs: "FORM 8-K",
"Infinity Provides Company Update and Reports Third Quarter 2017 Financial Results"
08/03/2017 8-K Quarterly results
Docs: "Infinity Provides Company Update and Reports Second Quarter 2017 Financial Results"
05/09/2017 8-K Form 8-K - Current report
03/14/2017 8-K Form 8-K - Current report
11/09/2016 8-K Form 8-K - Current report
08/09/2016 8-K Quarterly results
Docs: "INFINITY PROVIDES COMPANY UPDATE AND REPORTS SECOND QUARTER 2016 FINANCIAL RESULTS"
05/04/2016 8-K Quarterly results
Docs: "Controlled Equity OfferingSM Sales Agreement, by and between Infinity Pharmaceuticals, Inc. and Cantor Fitzgerald & Co",
"Opinion of Wilmer Cutler Pickering Hale and Dorr LLP",
"INFINITY PROVIDES COMPANY UPDATE AND REPORTS FIRST QUARTER 2016 FINANCIAL RESULTS"
11/07/2013 8-K Quarterly results
Docs: "INFINITY REPORTS THIRD QUARTER 2013 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE"
08/08/2013 8-K Quarterly results
Docs: "INFINITY REPORTS SECOND QUARTER 2013 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE"
05/07/2013 8-K Quarterly results
Docs: "INFINITY REPORTS FIRST QUARTER 2013 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE"
08/07/2012 8-K Quarterly results
Docs: "INFINITY REPORTS SECOND QUARTER 2012 FINANCIAL RESULTS"
05/08/2012 8-K Quarterly results
Docs: "INFINITY REPORTS FIRST QUARTER 2012 FINANCIAL RESULTS"
03/13/2012 8-K Form 8-K - Current report
11/08/2011 8-K Form 8-K - Current report
08/09/2011 8-K Quarterly results
Docs: "INFINITY REPORTS SECOND QUARTER 2011 FINANCIAL RESULTS"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy